| Not Yet Recruiting | A Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix DP, a Gonadotro NCT07457164 | Antev Ltd. | Phase 2 |
| Not Yet Recruiting | Lab Research Using Mini-tumors to Study Prostate Cancer Treatments NCT07004582 | Maastricht Radiation Oncology | — |
| Not Yet Recruiting | A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Ad NCT07198633 | Qilu Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate Cancer NCT07115446 | Hansoh BioMedical R&D Company | Phase 1 |
| Recruiting | Engage Psychosocial Intervention for Cancer Symptoms NCT06555588 | Duke University | N/A |
| Recruiting | HS-10502 Combination Treatment in Patients With Advanced Solid Tumors NCT06769425 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer NCT06335914 | University Health Network, Toronto | N/A |
| Active Not Recruiting | Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED) NCT06463457 | Atish Choudhury, MD | Phase 2 |
| Recruiting | European Registry of Next Generation Imaging in Advanced Prostate Cancer NCT06866782 | Fundacio Puigvert | — |
| Recruiting | PRORAD-5 PROstate RADiation in 5 Fractions: Phase II Five Fraction Radiotherapy for Patients With Advanced Pro NCT06369246 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer NCT06490328 | Dongkook Pharmaceutical Co., Ltd. | Phase 3 |
| Recruiting | Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT NCT06062745 | Brigham and Women's Hospital | Phase 1 |
| Recruiting | A Study of JNJ-87189401 Plus JNJ-78278343 for Advanced Prostate Cancer NCT06095089 | Janssen Research & Development, LLC | Phase 1 |
| Recruiting | Whole Body MRI in Oncology NCT06895291 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | — |
| Unknown | Phase 1/2 Clinical Study of HRS-4357 in Patients With Advanced Prostate Cancer NCT06006104 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) NCT05942001 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Recruiting | A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Me NCT05800665 | Genentech, Inc. | Phase 1 |
| Completed | Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Pr NCT05590793 | Ipsen | Phase 3 |
| Completed | The Study Will Evaluate if Leuprolide Mesylate is Safe and Effective in the Treatment of Subjects With Advance NCT06984159 | Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 3 |
| Terminated | A Study of Neoadjuvant Hormone Therapy in Patient With Advanced Prostate Cancer Undergoing Radical Prostatecto NCT03971110 | AstraZeneca | Phase 4 |
| Completed | Goserelin 10.8mg Injection in Treatment of Advanced Prostate Cancer NCT03936218 | Eurofarma Laboratorios S.A. | Phase 3 |
| Unknown | Whole Body Magnetic Resonance Imaging Study NCT04117594 | Royal Marsden NHS Foundation Trust | — |
| Active Not Recruiting | SRAM study_Postate Cancer NCT03938649 | CCTU | Phase 2 |
| Completed | Evaluation of PSMA-based PET as an Imaging Biomarker in Prostate Cancer NCT02420977 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | EARLY_Phase 1 |
| Unknown | TUPKRP Combined With MAB Therapy for LUTS/PCa NCT03701659 | The Third Xiangya Hospital of Central South University | N/A |
| Completed | Nivolumab With or Without Ipilimumab in Advanced Metastatic Cancer NCT03651271 | Parker Institute for Cancer Immunotherapy | Phase 2 |
| Active Not Recruiting | Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer NCT03511196 | H. Lee Moffitt Cancer Center and Research Institute | EARLY_Phase 1 |
| Terminated | Study of HPN424 in Patients With Advanced Prostate Cancer NCT03577028 | Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 1 / Phase 2 |
| Unknown | PROSENZA: Prospective Multi-Centre Study of Prognostic Factors in mCRPC Patients Treated With Enzalutamide. NCT02922218 | Centro Nacional de Investigaciones Oncologicas CARLOS III | — |
| Unknown | PRORADIUM: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Radium-223. NCT02925702 | Centro Nacional de Investigaciones Oncologicas CARLOS III | — |
| Completed | Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Tre NCT02234089 | Ferring Pharmaceuticals | — |
| Unknown | PROSABI: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Abiraterone Aceta NCT02787837 | Centro Nacional de Investigaciones Oncologicas CARLOS III | — |
| Unknown | PROSTAC: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Docetaxel or Caba NCT02362620 | Centro Nacional de Investigaciones Oncologicas CARLOS III | — |
| Withdrawn | Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treat NCT02035124 | SCRI Development Innovations, LLC | Phase 2 |
| Completed | A Long-term Observational Study Cohort in Patients With Advanced Prostate Cancer NCT01383863 | Ipsen | — |
| Completed | A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer NCT01306890 | Dendreon | — |
| Unknown | Prostate Cancer, Androgen Deprivation Withdrawal and Intermittent Chemotherapy NCT01224405 | University of Turin, Italy | Phase 3 |
| Completed | Evaluation of Prostate-Specific Antigen (PSA) Levels in Patients With Advanced Prostate Cancer Treated With Bi NCT00871585 | AstraZeneca | — |
| Completed | Lucrin® Depot Efficacy and Safety Monitoring Study in Patients With Advanced Prostate Cancer and Lower Urinary NCT01078545 | Abbott | — |